Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
2.530
+0.040 (1.61%)
At close: Oct 8, 2025, 4:00 PM EDT
2.580
+0.050 (1.98%)
After-hours: Oct 8, 2025, 7:12 PM EDT
Alzamend Neuro Employees
As of April 30, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$976,194
Market Cap
8.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Apr 30, 2025 | 7 | 0 | - |
Apr 30, 2024 | 7 | 0 | - |
Apr 30, 2023 | 7 | -1 | -12.50% |
Apr 30, 2022 | 8 | 2 | 33.33% |
Apr 30, 2021 | 6 | 2 | 50.00% |
Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALZN News
- 2 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 2 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 4 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 4 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 5 months ago - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 5 months ago - Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 5 months ago - Alzamend Neuro Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - GlobeNewsWire